StreetInsider.com News Articles

Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654291.html

Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654291.html

Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654291.html

Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew

Tue, 16 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260616/26654291.html

Form 8-K Immuneering Corp For: Jun 11

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647480.html

Form 8-K Immuneering Corp For: Jun 11

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647480.html

Form 8-K Immuneering Corp For: Jun 11

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647480.html

Form 8-K Immuneering Corp For: Jun 11

Mon, 15 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26647480.html

Immuneering names Andrew Gengos as chief financial officer

Mon, 15 Jun 2026 07:30:09 -0400

Immuneering Corporation (NASDAQ: IMRX) appointed Andrew Gengos as chief financial officer, effective July 16, 2026, according to a company statement. Gengos previously served as CFO and head of corporate development at Terns Pharmaceuticals, which Merck & Co. acquired for $6.7 billion.

At Immuneering, Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities. The company is advancing atebimetinib, its lead oncology candidate currently in Phase 3 trials, along with a pipeline of other deep cyclic inhibitors.

"Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Mon, 15 Jun 2026 07:30:00 -0400

- Former CFO of Terns Pharmaceuticals to join Immuneering -

- Seasoned public company CFO strengthens team with over 25 years of leadership in biotech –

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Mon, 15 Jun 2026 07:30:00 -0400

- Former CFO of Terns Pharmaceuticals to join Immuneering -

- Seasoned public company CFO strengthens team with over 25 years of leadership in biotech –

Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.

Thu, 11 Jun 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636955.html

Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.

Thu, 11 Jun 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636955.html

Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.

Thu, 11 Jun 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636955.html

Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.

Thu, 11 Jun 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260611/26636955.html

Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA

Thu, 11 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260611/26636937.html

Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA

Thu, 11 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260611/26636937.html

Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA

Thu, 11 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260611/26636937.html

Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA

Thu, 11 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260611/26636937.html

Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J

Thu, 11 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636922.html

Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J

Thu, 11 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636922.html

Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J

Thu, 11 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636922.html

Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J

Thu, 11 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260611/26636922.html

Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE

Thu, 11 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260611/26636888.html

Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE

Thu, 11 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260611/26636888.html